In clinical trials, digoxin, strophanthidin, and ouabain were found to be successful against several tumor-causing TFs such as HIF-α, NF-Kb, AP-1, and C-Myc, demonstrating the high selectivity of CGs against transcription alteration. This evidence concerns the gene FOS and neoplasm.